Industry › BioTech

Press Releases

GEN Announces Positive Phase 2 Clinical Trial Results for GN-037 Topical Cream in Patients With Mild to Moderate Plaque Psoriasis

Sep 25, 2024 21:00 HKT/SGT

康哲藥業：磷酸蘆可替尼乳膏（白癜風）中國上市許可申請已獲受理

Sep 24, 2024 21:46 HKT/SGT

Ainos、限られた治療法しかない希少疾患シェーグレン症候群に対するVELDONAの台湾臨床試験開始計画を発表

Sep 24, 2024 18:00 JST

Rozebalamin(R) for Injection 25 mg (Mecobalamin) Approved in Japan for Amyotrophic Lateral Sclerosis

Sep 24, 2024 15:06 HKT/SGT

Anticancer Agent "Tasfygo(R) Tablets 35mg" (Tasurgratinib Succinate) Approved in Japan for Biliary Tract Cancer with FGFR2 Gene Fusions or Rearrangements

Sep 24, 2024 14:01 HKT/SGT

Ainos、治療法が限られている希少疾患であるシェーグレン症候群の治療薬VELDONAの台湾での臨床試験開始計画を発表

Sep 19, 2024 21:00 JST

Ripple Therapeutics Announces Collaboration and Option-to-License Agreement with AbbVie to Develop Next-Generation Therapies for Glaucoma Management

Sep 17, 2024 20:30 HKT/SGT

君聖泰醫藥亮相香港國際生物科技論壇

Sep 17, 2024 15:00 HKT/SGT

LENVIMA(R) (lenvatinib) Plus KEYTRUDA(R) (pembrolizumab) in Combination With Transarterial Chemoembolization (TACE) Significantly Improved Progression-Free Survival Compared to TACE Alone in Patients With Unresectable, Non-Metastatic Hepatocellular Carcinoma (HCC)

Sep 17, 2024 09:08 HKT/SGT

君聖泰醫藥亮相香港國際生物科技論壇

Sep 16, 2024 14:53 HKT/SGT

君圣泰医药亮相香港国际生物科技论坛

Sep 13, 2024 18:22 HKT/SGT

EASD 2024 | HighTide Therapeutics Presents Oral Reports of Phase 2 Studies, Highlighting Benefits of Berberine Ursodeoxycholate (HTD1801)

Sep 11, 2024 12:00 HKT/SGT

EASD 2024 | 君圣泰医药口头报告熊去氧胆小檗碱（HTD1801）在T2DM中的两项事后分析

Sep 11, 2024 11:51 HKT/SGT

EASD 2024 | HighTide Therapeutics Presents Oral Reports of Phase 2 Studies, Highlighting Benefits of Berberine Ursodeoxycholate (HTD1801)

Sep 11, 2024 11:34 HKT/SGT

EASD 2024 | 君聖泰醫藥口頭報告熊去氧膽小檗碱（HTD1801）在T2DM中的兩項事後分析

Sep 11, 2024 11:16 HKT/SGT

Eisai Accelerates Progress in Oncology Research with New Data at ESMO Congress 2024

Sep 05, 2024 15:59 HKT/SGT

日本厚生勞動省批准了莫德納公司針對SARS-COV-2 JN.1變異株的COVID-19 mRNA疫苗的部分變更申請

Aug 24, 2024 08:00 HKT/SGT

日本厚生劳动省批准了莫德纳公司针对SARS-COV-2 JN.1变异株的COVID-19 mRNA疫苗的部分变更申请

Aug 24, 2024 08:00 HKT/SGT

Ministry of Health, Labour and Welfare in Japan Approves Partial Change Application for Moderna's COVID-19 mRNA Vaccine Targeting SARS-COV-2 Variant JN.1

Aug 24, 2024 08:00 HKT/SGT

Avantor Triumphs with Three Awards at Korea Biopharma Excellence Awards 2024

Aug 23, 2024 08:00 HKT/SGT